Nectar Lifesciences completes slump sale of pharma business to Ceph Lifesciences

Core Business DivestedStrategic Transactions View source PDF Explain this filing

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹14.72

prior close

₹14.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-4.5% vs market

On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.5

15m

+1.5

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-3.5+0.9-4.5

Next day

+8.0+0.8+7.2

+1.5+0.7+0.7

-0.5+1.3-1.8

-6.4+0.5-6.9

-4.9+0.4-5.2

+1.8-1.5+3.3

15d

+22.3-2.4+24.7

+43.1-4.4+47.5

+17.2-7.2+24.4

-8.4-5.0-3.4

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nectar Lifesciences has completed the slump sale of its active pharmaceutical ingredients (API) and formulations business to Ceph Lifesciences Private Limited, effective November 10, 2025. The related asset sale under the asset purchase agreement has also been completed. This follows the business transfer agreement signed on July 7, 2025.

Likely market impact

Core pharma business divested; what remains of company operations and use of sale proceeds will be key for shareholders.